Audrey Fresse

“Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers

Alexandre O. Gérard, Serena Romani, Audrey Fresse et al. · Therapies · 2020 · 144 citations · Full text

Drug Safety, Drug Interactions, Cardiovascular Toxicity +12

Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database

Alexandre O. Gérard, Audrey Laurain, Audrey Fresse et al. · Clinical Pharmacology & Therapeutics · 2020 · 67 citations

World Health Organization, Pharmacotherapy, Logistic Analysis +23

Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in COVID-19. An alleged past-resolved problem

Audrey Fresse, Delphine Viard, Serena Romani et al. · International Journal of Cardiology · 2020 · 22 citations · Full text

Long Covid, Cardiovascular Disease, Antiviral Therapy +5

Insights on the Evidence of Cardiotoxicity of Hydroxychloroquine Prior and During COVID‐19 Epidemic

Serena Romani, Alexandre O. Gérard, Audrey Fresse et al. · Clinical and Translational Science · 2020 · 17 citations · Full text

Disease Outbreak, Pharmacotherapy, Covid‐19 Epidemic +19

Immune checkpoint inhibitors-induced nephropathy: a French national survey

Alexandre O. Gérard, Marine Andreani, Audrey Fresse et al. · Cancer Immunology Immunotherapy · 2021 · 16 citations · Full text

Glomerulonephritis, Urology, Kidney Transplant +9